Restelli, U. et al. 2016. Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients. Farmeconomia. Health economics and therapeutic pathways. 17, 1 (Mar. 2016), 7–12. DOI:https://doi.org/10.7175/fe.v17i1.1225.